It's (painfully) obvious, revenue is not in Gerald's vernacular right now - or anytime in the near future - the game plan is on Research Use Only (RUO) launch of LymPro between now and 12/31 - as well as completing / closing the Lanza acquisition as quickly as possible. Gerald has specifically refered to LPC funding and IMHO, will continue to dilute-out the 1st 1-Bil. AS, in order to survive - as he moves the proverbial ball down court. Unfortunately we are either "in" with his financial plan or we are "out". He also addressed long term shareholder appreciation during the CC and directly tied it to the proposed spin-out of the Diagnostics Division. Question is, what happened to all the talk of shareholder value and shareholder appreciation these past few years? Simply stated, as a CEO, Gerald has to make the company look like it is always on the cusp of the next big break out - and in portraying the company as an eminent success, he is able to perform equity distribution (which is a colorful term for selling of cheap shares, more commonly called dilution). Gerald is very good at selling the sizzle I might add. In the infamous words of Gerald, "trust the science"